ABSTRACT
Introduction
Infarct healing is a complex biological process that occurs during the first 2 weeks after myocardial infarction (MI). [1] [2] [3] The quality of healing influences the outcome; impaired healing leads to infarct expansion and accelerated left ventricular remodeling. 4, 5 Reperfusion strategies, specifically thrombolytic and antiplatelet therapies, have remarkably improved the clinical outcome in patients with acute MI. However, beneficial effects of reperfusion therapies are limited by the amount of ischemic damage that occurs before reperfusion. Several studies have focused on developing adjunctive pharmacological interventions to enhance the myocardial tolerance to ischemia/reperfusion (IR) injury.
The receptor for advanced glycation end products (RAGE), a multiligand receptor of the immunoglobulin superfamily, interacts with distinct families of ligands that mediate diverse functions in a broad array of cell types, including cellular migration and activation of proinflammatory mechanisms. 6 Initially, RAGE was described as a receptor for advancedglycation end products (AGEs), which accumulate under hyperglycemic conditions. 6 Subsequent studies have shown that S100/calgranulins, amphoterin, and amyloid peptide can also bind to RAGE, causing the activation of signal transduction and modulation of gene expression. [7] [8] [9] In chronic disease states such as diabetes, immune/inflammatory foci, and neurodegenerative disorders, upregulation of RAGE was associated with tissue injury. 8, 9 Recently, RAGE was shown to modulate (1) the response to acute nerve injury 10 and (2) cell death-promoting mechanisms in severe hepatectomy. 11 Furthermore, the RAGE ligand S100B was shown to modulate cardiac hypertrophy and remodeling after MI. 12 RAGE silencing was reported to decrease MI. 13 However, the role of the RAGE in the treatment of arrhythmia is unknown. In this study, we evaluated whether RAGE decreases IR injury by using a rat MI model. Second, we evaluated whether RAGE could suppress arrhythmia in the rat IR model.
Methods

Animal Studies
All studies involving rats were approved by the Institutional The left anterior descending (LAD) artery was ligated for 1 h by using a 6-0 silk suture (Ethicon, Somerville, NJ), followed by reperfusion. Ischemia was confirmed by visual inspection of blanching in the myocardium distal to the occlusion site. In shamoperated rats, the same procedure was performed without LAD ligation and reperfusion. RAGE-siRNA/polyethyleneimine modified with deoxycholic acid (PEI-DA) nanocarriers were injected 1 h before surgical occlusion, and 3 intra-myocardial injections totaling 100 μL of RAGE-siRNA/PEI-DA nanocarriers (siRNA, 10 μM) solution in PBS were placed along the anterior and lateral aspects of the contracting wall bordering the infarct site. Rats were randomly divided into the following four groups: 1) control (sham operation, n = 10), 2) IR (IR only, n = 11), 3) IR+siRAGE (IR and RAGE-siRNA injection, n = 10), and 4) IR+scRNA (IR and scrambled siRNA injection, n = 9).
Ambulatory Holter monitoring was performed using a telemetry system (Telemetry Research, Auckland, New Zealand).
Infarct Size and Fibrotic Area Analysis
To analyze the fibrotic area in cardiac tissues, heart sections were stained with conventional hematoxylin and eosin and Masson's trichrome. The blue-colored fibrotic area was measured using MetaMorph software ver. 4.6 and was expressed as percent fibrosis (ratio of the fibrotic area to the total left ventricular area). To measure the infarct area, the hearts were sectioned transaxially and 
Optical Mapping
Rats (250-300 g) were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and xylazine (4 mg/kg). The chests were opened via median sternotomy, and the hearts were rapidly excised and immersed in cold Tyrode's solution (composition:
125 mM NaCl, 4.5 mM KCl, 0.25 mM MgCl2, 24 mM NaHCO3, 1.8 mM NaH2PO4, 1.8 mM CaCl2, and 5. 
Western Blotting
The rat hearts were homogenized before lysis. The protein concentration was determined using the Pierce BCA Protein 
Statistical Analysis
Data were expressed as the mean ± SEM. Student's t-tests with 
Results
RAGE-siRNA Treatment Attenuated IR Injury
To evaluate cardioprotective effects of RAGE-siRNA nanocarriers against IR injury, the extent of myocardial fibrosis and infarct size were assessed by histology by using Masson's trichrome staining and triphenyl tetrazolium chloride staining, respectively, at 7 days after treatment ( Figure 1A and B). The quantification of the fibrotic area revealed a markedly lower degree of left ventricular fibrosis in the RAGE-siRNA nanocarrier treatment group compared to the IR and IR+scRNA groups, as shown in Figure 1A . Specifically, the fibrotic area was reduced in the IR+siRAGE group from 32% to 10% of the left ventricular wall. In addition, treatment with RAGE-siRNA nanocarriers caused significant attenuation of myocardial infarct expansion after LAD ligation in the rat MI model ( Figure 1B ). The
IR+siRAGE group (14.2 ± 3.4%) showed a 3-fold reduction in degree of infarct expansion compared to IR (44.9 ± 7.5%) and
IR+scRNA (44.9 ± 6.8%) groups.
RAGE-siRNA Treatment Improved Survival Rate and Decreased Inducible VT or VF in IR Rats
The results of short-term modality showed that the IR+siRAGE group had a significantly better heart survival rate than IR and IR+scRNA groups ( Figure 2A ). Specifically, in the IR group, 6 (50%) of 11 rats died at 46 ± 14 min after acute myocardial infarction. No rats died in control and IR+siRAGE groups. These results indicate that potential cardioprotective effects of the RAGE-siRNA nanocarriers can be attributed mainly to enhanced RAGE suppression, leading to a reduced innate immune response after acute myocardial infarction. While spontaneous VT or VF were not observed in control rats, they were observed in 6 (65%) rats in the IR group (p=0.01). However, only 1 (10%) rat in the IR+siRAGE group had VT, showing a significant reduction in VT episodes after siRAGE injection in IR rats (p=0.03, Figure 2B ). Representative examples of induced VF are presented in Figure 2C . For the control (n=8), IR (n=8), IR+siRAGE (n=6), and IR+scRNA (n=6) groups, VT was induced in 0, 6 (75%), 0, and 4 (67%) rats, respectively. The IR group had higher inducible VT or VF than the control group (p=0.001). siRAGE prevented inducible VT or VF after MI (p=0.01). However, these protective effects were not observed in the IR+scRNA group ( Figure 2D ). These electric characteristics are shown for the normal zone, infarct border zone, and infarct zone in Figure 3 . APD90 values were determined to be shorter in the IR group than in the control Figure 5 illustrates AP from an IR heart before and during a transient VT ( Figure 5A ) and during a sustained VF ( Figure 5B ). Figure 5A ) exhibited a stable reentry pattern, with wavefronts emanating from a similar origin and propagating in a similar direction between beats. In contrast, during sustained VF (Figure 5Ba '-5Bg'), the origins of successive reentrant waves varied randomly and the arrhythmia was perpetuated by coexisting reentrant circuits maintained by the continuous annihilation and creation of daughter wavelets. 15 Voltage oscillations during VF were analyzed in a DF map ( Figure   5C ). The analysis showed that the normal zone ( Figure 5C②) had higher dominant frequencies than the infarct border zone ( Figure 5C① ) (25.8 ± 3.0 vs. 19.0 ± 2.3 Hz, p=0.01, Figure 5D ). 
RAGE and Arrhythmia
Increased VT Vulnerability in IR Model and Suppression by RAGE-siRNA Treatment
Activation maps during transient (a-g) VT (
RAGE Suppression Reduced Inflammatory Responses in IR Rats
Since the upregulation of RAGE is tightly associated with the inflammatory response, cytokine expression patterns were further verified in a rat IR model treated with RAGE-siRNA nanocarriers ( Figure 6 ). In general, at the site of inflammatory responses, interactions between RAGE and its various ligands caused the generation of proinflammatory cytokines such as IL-6 and TNF-α. Indeed, the levels of IL-6 and TNF-α were significantly increased above the normal range after acute IR. This enhanced production of the proinflammatory cytokines was dramatically reduced by RAGE-siRNA nanocarrier treatment, though negative-RAGE nanocarriers showed no antiinflammatory effects in the rat IR model.
Discussion
The main findings of this study were that IR hearts showed elevated levels of RAGE and higher susceptibility to VF. The IR ventricle had a slower CV and higher level of fibrosis and inflammation. The RAGE-siRNA polyplex significantly reversed fibrosis and inflammation, increased ventricular CV, and suppressed VF.
Post-infarct Remodeling: Inflammation and Cardioprotection
Immediately after ischemic injury, various intra-and intercellular pathways contribute to healing of the myocardial wound in order to restore tissue integrity and function. Activation of the immune system after cardiac injury follows the pattern of Figure 6 . RAGE suppression reduced inflammatory responses in IR rats. IL-6 and TNF-α were increased in IR and IR+scRNA, but not in control and IR+siRAGE rat hearts. Numbers in bars indicate the number of rats. IL-6, Interleukin 6; IR,ischemia/reperfusion; RAGE receptor for advanced glycation endproducts; TNF-α,tumor necrosis factor-α. RAGE is a key factor in myocardial IR injury, 13 an indicator of chronic heart failure severity, and an independent marker of coronary artery disease and its severity in patients with congestive heart failure. 16 RAGE affects the generation of inducible nitric oxide synthase, nitrite and nitrate, and cGMP in the heart, particularly after IR injury. The pharmacological blockade of RAGE protects the isolated perfused heart from damage and dysfunction. In the mouse model, release of lactate dehydrogenase was attenuated in RAGE-null hearts. Furthermore, protection in RAGE-null mice hearts was associated with improved functional and metabolic recovery. However, the improvement in electrophysiological changes by cardioprotection was not fully elucidated. In this study, increased fibrosis, TNF-α, and IL-6 were observed in IR injury. The RAGE-siRNA polyplex significantly reversed fibrosis and inflammation.
Improvement of Myocardial Conduction by Cardioprotection Therapy with RAGE-siRNA
Changes in ionic currents caused by acute ischemia were shown to modify refractoriness and propagation velocity in cardiac tissue.
The simulation showed that in the ischemic cell, K + accumulation outside the cell had a major effect on cell excitability by depolarizing resting membrane potential, and reducing sodium 
Anti-arrhythmic Effects of Cardioprotection Therapy by RAGE-siRNA
APDs of ischemic cells did not exhibit rate adaptation characteristic, causing flattening of the APD restitution curve. 17, 18 With the reduction in sodium channel availability and long recovery of excitability, the refractory period of ischemic tissue was significantly prolonged and could no longer be considered to be the same as APD. Therefore, global ischemia leads not only to a delayed but also to a non-uniform electrical restitution. The delay in electrical restitution may be causally related to the development of alternans of APD, whereas the dispersion of electrical restitution may produce electrical instability and set the stage for ischemia-related ventricular arrhythmias. 17, 18 The slope of the CV restitution curve increased both in the normal and ischemic regions when pacing cycle length was short; moreover, refractory period dispersion increased with shortening of pacing cycle length. 19 Therefore, dynamic changes in CV and dispersion of the refractory period were suggested to be the fundamental mechanisms of arrhythmia in the regional ischemic myocardium.
In this study, cardioprotection therapy by RAGE-siRNA reversed the changes in CV RK by IR injury.
Role of Heterogeneities in VF
Inflammatory cell infiltration and the myocardial structure destruction in the IR group were not observed in the IR+siRAGE group. The relative contribution of fixed versus dynamic heterogeneities in the mechanism of VF remains unclear. 20, 21 Regional myocardial ischemia is a clinically relevant condition in which very large macroscopic heterogeneities occur naturally.
Therefore, ischemia caused an increase in wavebreaks in the border zone and a decrease in wavebreaks in the ischemic zone, without a significant change in the nonischemic zone. This finding is consistent with the dominant-frequency distribution during ischemic VF: the average dominant frequency was significantly slower in the infarct zone than in the non-infarct zone, suggesting a large gradient in refractory periods across the border zone. 22 Cardioprotection therapy by RAGE-siRNA reduced tissue heterogeneity by reducing fibrosis and inflammation.
Conclusion
Our results revealed an association between RAGE and myocardial IR injury-associated cardiac dysfunction. The cardioprotection therapy with RAGE-siRNA polyplexes was effective in preventing fatal ventricular arrhythmia by reversing fibrosis and inflammation and increasing ventricular CV. We propose that RAGE-siRNA polyplexes combined with PE-DA can be used to exert cardioprotection in the heart, particularly after injury exacerbated by IR.
